Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If true, my short puts will expire worthless.
Congrats to the longs on the positive price action.
Just goes to show how an approach can change merely off the difference between not currently being invested and continuing to hold a long term investment. It changes the dynamics, along with the differences we have in investment style, risk tolerance and so on.
If I were to ever start regretting not investing in a stock on my watch list because it eventually went up without me, it would be a sad thing. I don't have to bet when (or if) the turnaround gets started simply by not owning the stock. [eom]
Patience looks to have been a virtue.
Price is holding up fairly well so far after hours and made a nice rebound from the initial selloff. Have to see what happens during market hours the next couple days - may sell some more puts if the implied vol gets high enough.
Don't see a need to buy equity just yet, will take what happens with the short puts.
Apparently, microcap daytraders have arrived en masse.
Suspect a promotion from one or more penny stock trade/investment services based on that kind of action. Once the bagholders are fed, price should drift back down to the prior level.
And AQB up another 6% so far today.
If I didn't know better, I'd think the market is trying to make me feel bad for not adding under $13.
Seriously though, it is still too early to know what the market thinks it is worth. It has held $12 so far and I'll take that as a positive.
Someone else with better knowledge of the NASH landscape might have a comment on that.
There is a lot of unmet need in NASH. So I would expect more BTD designations until the need is better met.
They may not know yet. It's not like they have to use it immediately.
We still don't know what it was intended for. If it was for HCV they now have it available for something else. Was it worthwhile as insurance against a BTD?
There are several in house possibilities and also at least some chance of using it on something yet to be acquired.
ENTA management strikes as being very shrewd and thorough in regards to cash deployment,
for a company like OCRX with modest financial resources.
Looks like an event run-up and sell the news.
Common price pattern.
Less than a starter position, but yes.
Have to get the first mistake out of the way cheaply. Worst luck and all that.
free shares of AQB in the partial spin-off may be inclined to sell
The latest AQB quote I see on nasdaq.com is $24.00, but this price may be an artifact insofar as today is the first day of Nasdaq trading and the ABTU.L closing price today (on the AIM/London exchange) was 1400 GBp, which equates to $17.27 at the current exchange rate. If the $24.00 Nasdaq price is legitimate, then AQB's current enterprise value is about $140M.
AQB
Have you done any valuation work on this?
ENTA
Enanta has concluded the proof-of-concept study of EDP-494, its cyclophilin inhibitor candidate, in patients with HCV genotypes 1 and 3. Given the high SVR rates in most of the underserved HCV populations demonstrated in phase 3 studies of treatment with G/P in our partnered HCV program, Enanta now believes that G/P has the best and most timely potential for Enanta to participate in the treatment of those HCV patients who have failed on other treatment regimens. Therefore, Enanta has decided to stop further development of EDP-494 and to focus its efforts on its wholly-owned programs in NASH/PBC, RSV and HBV.
[ALR]
Dew, I saw this in your Charity Contest portfolio at 8%. It does not look like a typical entry - anything from you on why it is in your portfolio would be useful. TIA
PVCT
You missed that the acting CEO of PVCT was the CFO at the time Dees submitted all those travel receipts for payment which PVCT is now trying to recover, and blew his oversight function (there are less charitable ways to describe what happened.)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 27, 2016, the Board of Directors of Provectus Biopharmaceuticals, Inc. (the “Company”) unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the Company and each of its subsidiaries, including Interim Chief Executive Officer and Chief Operating Officer of the Company, for cause, in accordance with the terms of his employment agreement based on the results of the investigation conducted by a Special Committee of the Company’s Board of Directors regarding improper expense advancements and reimbursements to Mr. Culpepper.
As previously reported, the Board of Directors has established a search committee to identify a permanent Chief Executive Officer. In the interim, Timothy C. Scott, Ph.D., the Company’s President, will perform the functions of the chief executive officer position in his capacity as President while the chief executive officer position remains vacant.
Is there forward royalty as well?
From the $GILD - $MRK verdict. pic.twitter.com/5g8ueGchzy
— Matthew Herper (@matthewherper) December 15, 2016
FDA
President-elect Donald Trump’s transition team is considering a Silicon Valley investor close to billionaire Peter Thiel to head the Food and Drug Administration, according to people familiar with the matter.
Jim O’Neill, the Thiel associate, hasn’t been officially selected, according to the people, who asked to remain anonymous because the decision process is private, and the Trump team could still go in another direction.
“We should reform FDA so there is approving drugs after their sponsors have demonstrated safety -- and let people start using them, at their own risk, but not much risk of safety,” O’Neill said in a speech at an August 2014 conference called Rejuvenation Biotechnology. “Let’s prove efficacy after they’ve been legalized.”
Am curious what you think of WFM at about 30-31 under the current tax structure and if there are no favorable (or unfavorable) tax changes?
i.e. How does the business look a few years down the road relative to now, and what is that currently worth?
I was personally comfortable shorting puts for short term gains around 27 when the price was in the 28-29 range and volatility was high, prepared to hold if assigned. Different situation. LOL.
Top ten sources of B12 in food:
As two of the top ten sources are listed as fortified, they are supplements rather than food sources. Just a quibble.
(including the CEO's exercise-and-hold transaction: #msg-124809319) was a harbinger of a higher share price.
Eschew away. What Rx volume do you see? ( $$$ sales numbers are obv a separate but related issue)
Are your views unchanged from 3 years ago?
[ABBV/ENTA]
Very nice. Should be highly competitive. I still have no idea how to value it though. Any current views on the "cliff"?
Disclaimer: I still have no position since taking long term gains other than a quick flip this summer.
...the ATM itself is raising money. Whether the ATM or an underwritten offering does more damage to the share price in the short run is debatable.
p.s. I like the new $0.05 tick size for this stock.
[OT] Cervical traction devices
Does anyone have knowledge of cervical traction devices, or can specifically recommend a make or model?
The 'cheaper' models that go around the front of the neck and/or require a doorway and/or a weighted bag to function are non-starters.
Thanks in advance.
For this ACID TEST results: this week thru 1:30 PM Fri
XBI OFF 5.9%;
IBB OFF 5.5%;
NWBO+10.1%;
your POOR example
Still superior to NWBO IMHO, and still in business at last check, although that is beside the point.
All that said - I agree PVCT is not comparable to NWBO. They are superior to NWBO. Not that that is worth anything mind you.
[bagholders]
*NYSE TO SUSPEND TRADING IN PROVECTUS BIOPHARMACEUTICALS $PVCT *NYSE CITES `ABNORMALLY LOW TRADING PRICE' OF PROVECTUS
h/t zach ?@zbiotech on twitter
Really bad management, balance sheet. Irrespective of whether the drug candidate works (or works well enough to matter.)
Making a fresh batch of popcorn.
In this particular case it also comes along with
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 14, 2016
To the Stockholders of Provectus Biopharmaceuticals, Inc.:
NOTICE IS HEREBY GIVEN that a special meeting of Stockholders (the “Special Meeting”) of Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) will be held on Monday, November 14, 2016 at 1:00 p.m. Eastern Standard Time at the offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, located at 265 Brookview Centre Way, Suite 600, Knoxville, TN 37919. The Special Meeting is being held for the following purposes:
1. To approve and adopt an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of common stock, par value $.001 per share (“common stock”), that we are authorized to issue from 400,000,000 to 1,000,000,000 shares; and
2. To authorize our Board of Directors to amend our Certificate of Incorporation, as amended, to effect a reverse stock split of our common stock at a ratio of between 1-for-10 and 1-for-50, such ratio to be determined by our Board of Directors in its discretion.
This fact is unassailable:
There are no failed drugs, only imprecise ways of testing them in all the infinite combinations and environments.
And there lies the wiggle room for statement which have enormous stupidity.
[OT]
https://medium.com/@InOurLabs/the-noise-miners-cffe6c14b626#.z3qav5qu8
A bit of humor the board can appreciate. A brief snip below.
When the light met the walls of the tunnel, I saw brilliant noise dancing all about. Here, the shiny gold glint of a social psychology experiment that can support any hypothesis regardless of the results; there, the dazzling reds, greens and blues of a brain imaging study with five participants. Nowhere else have I seen such exquisite noise.
GLTU
PVCT is NOT comparable to NWBO
Has one every encountered a deep into Ph3 clinical and valued at less than $60 mln? where Opdivo, Keytruda and those other laggards need what NWBO offers.
HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths. Mylan also intends to continue to market and distribute branded EpiPen®.
[PVCT] Probably best to stay away.
There are balance sheet and management issues that would make an investment difficult even if the drug is going to be successful in the current phase 3 trial, and that is not a given.
ADXS: Ironic that with your exposure to ADXS pre O'Connor that with his track record and tenacity you did not monitor it with O'Connor's arrival 2013.
AND in a roundabout way how all of the above gives me even more enthusiasm about NWBO!
I'm not sure. Something would have to excite me enough to restart diligence for what would likely never be more than a minor position. It's easier to get excited about something 'new'.